REG-MD Medical Group Investments Plc MD Medical Group Investments Plc: MD Medical Group maintains strong EBITDA margin
05/09/2022 08:15
============
MD Medical Group Investments Plc (MDMG)
MD Medical Group Investments Plc: MD Medical Group maintains strong EBITDA
margin
05-Sep-2022 / 10:00 MSK
Dissemination of a Regulatory Announcement that contains inside
information in accordance with the Market Abuse Regulation (MAR),
transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
══════════════════════════════════════════════════════════════════════════
MD Medical Group maintains strong EBITDA margin
5 September 2022 – MD Medical Group Investments Plc (“MD Medical Group,”
“MDMG,” the “Group” or the “Company” – LSE and MOEX: MDMG), a leading
Russian private healthcare provider, announces its audited consolidated
financial statements for the 6 months ended 30 June 2022 under
International Financial Reporting Standards (IFRS).
Key financial highlights for 1H 2022:
• Total revenue increased by 1.3% year-on-year (y-o-y) to
RUB 12,159 mln.
• EBITDA went down by 5.8% y-o-y to RUB 3,559 mln. EBITDA margin dropped
by 2.2 p.p. y-o-y to 29.3%.
• Adjusted Net profit decreased by 9.4% y-o-y to RUB 2,393 mln. Adjusted
Net profit margin was 19.7%.
• Operational cash flow declined by 15.9% y-o-y to RUB 3,132 mln.
• Capex amounted to RUB 762 mln, up 7.0% y-o-y. Investments were mainly
allocated towards the launch of new projects: MD Lakhta in
St Petersburg, MD Tyumen-2 and an out-patient clinic in Yekaterinburg.
• As at 30 June 2022, the Group’s Net Cash position stood at RUB 85 mln.
The Net Cash position to EBITDA ratio was 0.0x.
Key operational highlights for 1H 2022 1 1 :
• Total out-patient treatments decreased slightly, by 2.1% y-o-y, to
878,458.
• Total in-patient treatments decreased by 7.4% y-o-y to 70,937.
• Total IVF cycles increased by 0.8% y-o-y to 8,223.
• Total deliveries increased by 2.0% y-o-y to 4,109.
Key events during 1H 2022 and after the reporting period:
• Hospital launched in St Petersburg. In January 2022, MD Medical Group
opened a new multi-functional hospital MD Lakhta in St Petersburg. Its
core business is women’s and children’s healthcare with a focus on
childbirth and gynaecological surgery. Total investments in the
project amounted to circa RUB 2 bln.
• Hospital launched in Tyumen. In February 2022, MD Medical Group
launched a new multi-disciplinary hospital MD Tyumen-2. Total
investments in the project amounted to approximately RUB 1 bln.
• Novosibirsk Centre for Reproductive Medicine renovated. On
16 June 2022, MD Medical Group completed the renovation of its medical
centre in Novosibirsk, increasing its capacity to 1,000 IVF cycles per
year. Total investments in the project amounted to some RUB 23 mln.
• Medical centre opened in Moscow. On 23 June 2022, MD Medical Group
opened a new out-patient medical centre, Mother & Child Butovo, with a
capacity of 30,000 visits per year. Total investments in the project
amounted to circa RUB 16 mln.
• MGIMO Med University launched. On 1 September 2022, MD Medical Group
in cooperation with the Moscow State Institute of International
Relations (MGIMO) opened medical university MGIMO Med.
• VTB loan repaid early. In Q3 2022, MD Medical Group repaid the loan it
had taken out from VTB in 2018 by settling all outstanding obligations
in the amount of RUB 2,166 mln ahead of schedule.
1H 2022 Financial Highlights
RUB mln 1H2022 1H2021 change
Revenue 12,159 12,009 1.3%
Hospitals in Moscow 6,355 6,641 (4.3%)
Hospitals in regions 3,087 2,746 12.4%
Out-patient clinics in Moscow and MR 1,281 1,129 13.5%
Out-patient clinics in regions 1,430 1,485 (3.7%)
Managing company and other 6 7 (14.3%)
Gross profit 4,514 4,550 (0.8%)
Gross profit margin,% 37.1% 37.9% (0.8p.p.)
EBITDA 3,559 3,777 (5.8%)
EBITDA margin,% 29.3% 31.5% (2.2p.p.)
EBIT 1,442 2,977 (51.6%)
EBIT margin,% 11.9% 24.8% (12.9 p.p.)
FX loss (198) (42) 369.1%
Net finance expenses (134) (242) (44.5%)
Profit before tax 1,110 2,693 (58.8%)
Taxes (3) (6) (37.2%)
Net income 1,106 2,688 (58.8%)
Adjusted Net income 2,393 2,643 (9.4%)
Adjusted Net income margin,% 19.7% 22.4% (2.7 p.p.)
Revenue
In 1H 2022, MD Medical Group’s total Revenue increased by 1.3% y-o-y to
RUB 12,159 mln. The growth was mainly driven by a stable demand for IVF in
Moscow and the Moscow Region (revenue from IVF up 26.4% y-o-y), on-target
capacity utilisation rates at regional hospitals (revenue up 12.4% y-o-y)
amid a post-COVID recovery in demand for medical services, and strong
performance of new projects – MD Lakhta and the medical cluster in Tyumen.
Revenue from medical services not related to women’s and children’s health
accounted for 48.9% of total revenue, down from 51.3% in 1H 2021.
1H 2022 Key Operating Expenses
RUB mln 1H2022 1H2021 change
Payroll and Social contributions 5,110 4,664 9.6%
as % of total Revenue 42.0% 38.8% 3.2p.p.
Material expenses 2,496 2,649 (5.8%)
as % of total Revenue 20.5% 22.1% (1.6p.p.)
Medical services expenses 152 169 (10.5%)
as % of total Revenue 1.2% 1.4% (0,2p.p.)
Functional expenses 2 2 168 127 32.5%
as % of total Revenue 1.4% 1.1% 0.3p.p.
Gross profit
Gross profit in 1H 2022 declined by a marginal 0.8% y-o-y to
RUB 4,514 mln. Gross profit margin decreased by 0.8 p.p. y-o-y to 37.1%
primarily due to a rise in personnel costs as a result of business
expansion associated with the launch of MD Lakhta and MD Tyumen-2.
Impact of key expenses
In the reporting period, the Company's key expenses remained tightly
controlled and slightly increased by 1.8 p.p. y-o-y as a percentage of
revenue (to 65.2%) amid the growth of personnel costs and functional
expenses.
The share of personnel costs grew by 3.2 p.p. y-o-y as a percentage of
Revenue (to 42.0%) mainly due to a decline in COVID-19 diagnostic and
treatment services (resulting from a higher share of fixed costs) and the
opening of new facilities (MD Lakhta and MD Tyumen-2) and their gradual
ramp-up to design capacity.
The share of materials expenses decreased by 1.6 p.p. y-o-y as a
percentage of Revenue (to 20.5%) on the back of a reduction in
material-intensive services in the Company's portfolio, including therapy
related to COVID-19.
The share of medical services expenses declined by 0.2 p.p. y-o-y as a
percentage of Revenue (to 1.2%) due to the gradual vertical integration of
business processes, including the opening of the Company’s own laboratory
and data processing centre.
The share of functional expenses increased by 0.3 p.p. y-o-y as a
percentage of Revenue (to 1.4%), driven by the growth in marketing
expenses amid the Group’s business expansion.
EBITDA
EBITDA declined by 5.8% y-o-y and amounted to RUB 3,559 mln in 1H 2022.
EBITDA margin decreased by 2.2 p.p. y-o-y to 29.3% due to a drop in
revenue from COVID-19 diagnostic and treatment services.
Operating profit
Following impairment testing in 1H 2022, the Company recognised impairment
of investments made in the previous periods, including fixed assets of the
Ufa clinical hospital (opened in 2014) and goodwill of the Novokuznetsk
out-patient clinic (acquired in 2015) on the back of an unfavourable macro
environment. In addition, in the reporting period, the Group recognised a
RUB 85 mln impairment of previously acquired construction documents due to
the change in plans to build a clinic in St Petersburg. Total impairment
recognised in 1H 2022 was RUB 1,287 mln.
As a result, Operating profit dropped by 51.6% y-o-y to RUB 1,442 mln in
1H 2022, with an Operating profit margin of 11.9%.
Adjusted Net profit
In 1H 2022, FX loss amounted to RUB 198 mln. The 4.7x growth as at the end
of the reporting period was attributable to a 31.1% rouble appreciation
against the US dollar as compared to the beginning of the year.
As a result, the Company's Adjusted Net profit decreased by 9.4% y-o-y to
RUB 2,393 mln in 1H 2022. Adjusted Net profit margin dropped by 2.7 p.p.
y-o-y to 19.7%.
Key cash flow statement figures
RUB mln 1H2022 1H2021 change
Operating cash flow before Working capital changes 3,552 3,843 (7.6%)
Changes in Working capital (415) (117) 254.6%
Taxes (5) (2) 151.3%
Cash from operating activities 3,132 3,724 (15.9%)
Cash used in investing activities (565) (758) (25.5%)
Cash used in financing activities (1,249) (2,592) (51.8%)
Cash and cash equivalents increase 1,317 374 252.4%
In 1H 2022, Operating cash flow before changes in working capital
decreased by 7.6% y-o-y to RUB 3,552 mln as a result of the decline in
EBITDA.
Working capital
RUB mln June 30, 2022 December 31, 2021
Inventories 1,156 1,165
Accounts receivable 1,171 1,112
Accounts payable (2,180) (2,537)
Contract liabilities (1,976) (1,990)
The Company has historically maintained negative Working capital as a
source of additional financing. In 1H 2022, Working capital remained
negative at RUB (1,829) mln and amounted to 7.5% of Revenue.
In the reporting period, Operational cash flow decreased by 15.9% y-o-y to
RUB 3,132 mln, primarily due to the changes in Working capital caused by
the update of medicine and consumable supply terms as suppliers switched
from deferred payment by instalments to advance payment.
Cash used for investing activities, mainly consisting of capital
expenditures and proceeds from short-term deposits, amounted to
RUB 565 mln.
Total Capex increased by 7.0% y-o-y to RUB 762 mln in 1H 2022. The growth
was driven by the completion of construction at MD Lakhta, MD Tyumen-2,
and MD Lab test collection points.
In 1H 2022, cash outflows related to financing activities amounted to
RUB 1,249 mln vs RUB 2,592 mln in 1H 2021. The decrease came in as the
Company did not pay dividends for 2021.
As at 30 June 2022, net cash increased by RUB 1,115 mln to RUB 4,704 mln.
Debt portfolio
RUB mln June 30, 2022 December 31, 2021
Total debt 4,619 3 3 5,513 4 4
Short-term debt 1,677 1,786
Long-term debt 2,943 3,727
Cash and cash equivalents 4,704 3,590
Net debt / (Net Cash position) (85) 1,923
Net debt/(Net cash position) / EBITDA 0.0х 0.5х
The Group's debt decreased by 16.2% y-o-y to RUB 4,619 mln as at the end
of 1H 2022 mainly due to the repayment of RUB 858 mln towards the
principal balance. Cash balance grew by 31.1% to RUB 4,704 mln as at
30 June 2022 vs RUB 3,590 mln as at 31 December 2021.
As at 30 June 2022, the Company’s Net cash position amounted to
RUB 85 mln. The Company's debt is fully denominated in roubles. The Net
Cash position to EBITDA ratio as at 30 June 2022 was 0.0x.
Notes:
1. Minor deviations in the calculation of totals, subtotals and/or
percent changes are due to rounding
2. The Group’s consolidated financial statements are available on the
Group’s website: 5 www.mcclinics.com/investors/financial-reports/
***
For further information please contact:
Investors
Battalova Renata
Investor Relations Director
Tel.: +7 917 294 28 82
r.battalova@mcclinics.ru
About MD Medical Group
MD Medical Group is a leading provider in the Russian private healthcare
service market. The Company manages 50 modern healthcare facilities,
including 10 hospitals and 40 out-patient clinics in 25 regions of Russia.
In 2021, MD Medical Group's revenue amounted to RUB 25.2 bln while EBITDA
amounted to RUB 8.3 bln. The Company's GDRs are traded on London Stock
Exchange (LSE: MDMG) and Moscow Exchange (MOEX: MDMG).
Forward-Looking Statements:
This press release contains forward-looking statements, which are based on
the Company’s current expectations and assumptions and may involve known
and unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or implied
in such statements. The forward-looking statements contained in this press
release are based on past trends or activities and should not be taken
that such trends or activities will continue in the future. It is believed
that the expectations reflected in these statements are reasonable, but
they may be affected by a number of variables which could cause actual
results or trends to differ materially, including, but not limited to:
conditions in the market, market position of the Company, earnings,
financial position, cash flows, return on capital and operating margins,
anticipated investments and economic conditions; the Company’s ability to
obtain capital/additional finance; a reduction in demand by customers; an
increase in competition; an unexpected decline in revenue or
profitability; legislative, fiscal and regulatory developments, including,
but not limited to, changes in environmental and health and safety
regulations; exchange rate fluctuations; retention of senior management;
the maintenance of labour relations; fluctuations in the cost of input
costs; and operating and financial restrictions as a result of financing
arrangements. No statement in this press release is intended to constitute
a profit forecast, nor should any statements be interpreted to mean that
earnings or earnings per share will necessarily be greater or lesser than
those for the relevant preceding financial periods for the Company. Each
forward-looking statement relates only as of the date of the particular
statement.
Use of non-IFRS indicators
As part of disclosing the Group’s financial results under IFRS, we use the
following non-IFRS indicator: Adjusted net profit.
We believe Adjusted Net profit to be instrumental for investors and
analysts in assessing the core operating performance of the Company and
analysing comparable results for different periods, excluding one-off
gains or losses.
Adjusted Net profit means net profit under IFRS plus (1) impairment loss
on goodwill; (2) impairment loss on fixed assets; (3) impairment loss on
work in progress; minus (4) other income from property tax recovery.
Impairment loss on goodwill and fixed assets
As macro environment became more challenging in 1H 2022, the Group
recognised a one-off RUB 201 mln impairment loss on goodwill of the
Novokuznetsk out-patient clinic and a one-off RUB 1,000 mln impairment
loss on fixed assets of the Ufa clinical hospital (the excess of the fair
value of the goodwill / fixed assets over their book value).
Impairment loss on work in progress
Adjusted net profit for 1H 2022 does not include a RUB 85 mln impairment
loss on work in progress related to construction documents and the change
in the Group's plans to build a clinic in St Petersburg.
Other income from property tax recovery
Adjusted net profit for 1H 2021 does not include other income from
property tax recovery in the amount of RUB 45 mln.
══════════════════════════════════════════════════════════════════════════
6 1 Detailed information on operational results can be found in the
following 7 press release from 1 August 2022
8 2 Functional expenses include marketing, IT, client service costs,
staff training and communication services
9 3 Including RUB 108 million of short-term lease and RUB 545 million
of long-term lease
10 4 Including RUB 97 million of short-term lease and RUB 597 million
of long-term lease
══════════════════════════════════════════════════════════════════════════
ISIN: US55279C2008
Category Code: IR
TIDM: MDMG
LEI Code: 213800XKI6VHY4JBS612
Sequence No.: 185739
EQS News ID: 1434575
End of Announcement EQS News Service
══════════════════════════════════════════════════════════════════════════
11 fncls.ssp?fn=show_t_gif&application_id=1434575&application_name=news&site_id=reuters9
References
Visible links
1. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftn1
2. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftn2
3. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftn3
4. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftn4
5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d46a9e74936d3142b2884d636fb0891f&application_id=1434575&site_id=reuters9&application_name=news
6. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftnref1
7. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=02d7dc19b5c7415fd44b33ae8f7f70e9&application_id=1434575&site_id=reuters9&application_name=news
8. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftnref2
9. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftnref3
10. file:///data/ucdp/tmp/xhtmlconvert_parsn_eqs_89AQVciz.html#_ftnref4
============Recent news on MD Medical Investments
See all newsREG-MD Medical Group Investments Plc MD Medical Group Investments Plc: MD Medical Group announces cancellation of listing on LSE
AnnouncementREG - Stock Exch Notice MD Medical Group - Cancellation - MD Medical Group Investments plc
AnnouncementREG-MD Medical Group Investments Plc MD Medical Group Investments Plc: MD Medical Group announces intention to delist GDRs from the LSE
AnnouncementREG-MD Medical Group Investments Plc MD Medical Group Investments Plc: MD Medical Group announces operating results for Q1 2023
AnnouncementREG-MD Medical Group Investments Plc MD Medical Group Investments Plc: The results of the Annual General Meeting of shareholders
Announcement